Johnson & Johnson

Whether Johnson & Johnson is a good stock to buy depends on an investor’s goals, tolerance for risk and investment horizon. From a long‑term, value‑oriented perspective, J&J is often viewed as a defensive healthcare leader with a strong balance sheet, consistent free cash flow, and a history of dividend increases spanning more than six decades. It offers exposure to pharmaceuticals and medical technology – sectors with more predictable demand compared with cyclical industries. Analyst consensus tends toward a Moderate Buy, with average 12‑month price targets suggesting potential upside and a steady earnings growth trajectory. Morgan Stanley, for example, upgraded J&J to Overweight, citing confidence in future growth and a stronger earnings outlook through 2030. Financial forecasts also project expansion in both revenue and EPS over the next several years, driven by strong oncology sales and pipeline catalysts. J&J’s diversified revenue mix and leadership in high‑growth therapeutic areas add resilience, while its dividend yield offers an income component appealing to conservative investors. However, risks remain. The company deals with ongoing litigation, particularly relating to talc products, and must contend with competitive pressures, patent expirations and regulatory challenges, all of which can impact valuations and sentiment. Additionally, growth may be more moderate than high‑flying tech peers, so investors seeking significant capital gains might find J&J better suited as a core, defensive holding rather than a rapid growth play. Overall, it typically appeals to long‑term, income‑oriented investors who value stability, diversified healthcare exposure and consistent cash returns.